Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer

Table 3 Impact of other prognostic factors on overall survival

Predictor	n	Median survival in mo	P value1
Sex			0.884
Male	60	49
Female	42	57
Age			0.147
< 50 yr	27	38
≥ 50 yr	75	49
Preoperative BMI			0.423
< 18.5	4	4
18.5-25	49	53
25-30	35	51
> 30	14	49
ASA score			0.457
1-2	49	49
3-4	53	57
Primary tumour location			0.620
Colon	91	49
Rectum	11	23
Primary T-stage			0.669
T1-3	38	49
T4a	40	30
T4b	22	Not reached
Primary nodal stage			0.013a
N0	26	88
N1	31	51
N2a	19	30
N2b	23	18
Primary distant metastasis			0.046a
M0	36	57
M+	62	35
Primary tumour grading			0.010a
G2	59	51
G3	34	29
Primary tumour resection			0.035a
R0	76	51
R1	20	30
R2	4	16
Cytoreduction level			< 0.001b
CC0	89	49
CC1	10	12
CC2-3 + palliative resections	3	3
PCI-score			< 0.001b
< 10	56	51
10-20	29	27
20-30	11	10
> 30	5	9
Operation extent
Partial colectomy	55	53	0.189
No colon resection	47	31
Small bowel resection	49	30	0.355
No small bowel resection	53	51
Liver metastasis resection	42	27	0.024a
No liver resection	60	51
HIPEC regimen			0.139
MMC	34	30
Oxaliplatin/5-FU	68	Not reached

¹Univariate analysis by Kaplan-Meier method with log-rank test for the comparison of subgroups.

^aP < 0.05.

^bP < 0.01. 5-FU: 5-Fluorouracil; ASA: American Society of Anesthesiologists; BMI: Body mass index; HIPEC: Hyperthermic intraperitoneal chemotherapy; MMC: Mitomycin C; PCI: Peritoneal cancer index.